ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

Boosting Healthy Red Blood Cell Production to Target Anemia in MDS and Beta-Thalassemia

A new class of agents developed to enhance the production of healthy red blood cells (RBCs) provides a much-needed alternative to current treatment options...

New Treatment Option for Relapsed or Refractory Multiple Myeloma

Findings from a large clinical trial could pave the way for a new standard therapeutic approach to patients with refractory or relapsed and refractory...

New Drug Class Could Fill Unmet Need in Treatment of Multiple Myeloma

A new class of drugs designed to attack malignant plasma cells could offer patients with multiple myeloma new treatment options, according to early clinical...

Brentuximab Vedotin Delivers Clinical Results in Both Pre- and Post-Transplant Hodgkin Lymphoma

Brentuximab vedotin, an antibody-drug conjugate that targets CD30-positive cells, was the focus of much attention at the 56th ASH Annual Meeting. Two studies highlighted...

Update on Idelalisib + Rituximab in Relapsed and Elderly CLL Patients

The combination of idelalisib with rituximab prolonged progression-free survival (PFS) for patients with relapsed chronic lymphocytic leukemia (CLL), according to an oral presentation at...

Rising Cost of Cancer Drugs: Is There an End in Sight?

In 2013, U.S. health-care spending continued its relentless climb, reaching $2.9 trillion, far outspending any other developed nation.¹ About $271.1 billion of that – or almost one...

For ASCT in Myeloma, Does One Size Fit All?

SAN FRANCISCO — Drug development for multiple myeloma in the last decade has reached an unprecedented pace, expanding to include regimens with novel agents like...

Addition of Third Drug to Multiple Myeloma Regimen Slows Progression of Disease

A new research study has found that adding carfilzomib to a treatment regimen of lenalidomide and dexamethasone significantly improved progression-free survival (PFS) in patients...

New Compound Boosts Healthy Red Blood Cell Production, Lowers Anemia Burden in β-Thalassemia

ACE-536, a recombinant fusion protein containing modified activin receptor type IIB and IgG Fc, has shown promising results in the treatment of β-thalassemia, reducing the need for...

HSCT Could Become Standard of Care for HIV-Positive Patients with Lymphoma

Results from a multi-institutional trial presented at ASH 2014 debunk the common myth that HIV-positive patients with lymphoma might not be suitable for autologous hematopoietic stem cell...
Advertisement

Current Issue

March 2019, Volume 5, Issue 4

This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.